Le Lézard
Classified in: Health
Subjects: CHI, RCL

Perrigo Announces Voluntary Recall of Limited Quantity of Nestlé® Good Start Soothetm 942g Infant Formula


DUBLIN, March 17, 2023 /CNW/ - Perrigo Company plc is issuing a voluntary recall of one sku of Nestlé® Good Start Soothetm 942g Infant Formula in Canada, that was manufactured at the Company's Gateway Eau Claire, Wisconsin manufacturing facility in January 2023. This product is being recalled out of an abundance of caution due to the potential presence of Cronobacter sakazakii.

Importantly, no distributed product has tested positive for the presence of this bacteria, and no adverse events have been reported. No other Nestlé® Good Start products in Canada are affected by this recall.

Affected Product in Canada:

Affected Product in Canada - Perrigo Announces Voluntary Recall of Limited Quantity of Nestlé® Good Start Soothetm 942g Infant Formula (CNW Group/Perrigo)

Cronobacter sakazakii is a bacteria commonly found in the environment. In most people it causes no symptoms but in some, particularly premature infants, infants under 2 months of age or infants with weakened immune systems fever, poor feeding, excessive crying or low energy as well as other serious symptoms can occur.

This product is sold at retailers across Canada. Consumers who may have purchased the product should look for the following lot codes and expiry dates:

Nestlé® Good Start Soothetm 942g:
301757651Z ? EXP 2024 JL 18
301757652Z ? EXP 2024 JL 18
301857651Z ? EXP 2024 JL 19

We have been working with the Canadian Food Inspection Agency (CFIA) and are immediately informing our customers who received these products and arranging for them be removed from store shelves. 

Consumers who have purchased this product should stop using the product, contact Nestlé Consumer Services for reimbursement and then dispose of the product. The contact information is as follows:

Phone: 1-800-387 4636 from 10:00 a.m. to 4:00 p.m. EST

Email : [email protected] or https://www.madewithnestle.ca/help/contact 

For over 130 years, Perrigo has been committed to meeting the needs of consumers?and the quality and safety of our products is our highest priority. We have numerous regulatory approved procedures throughout the manufacturing process to control for Cronobacter sakazakii. Every batch of infant formula is tested to make certain it meets stringent nutritional, safety, quality, and regulatory requirements. As part of our rigorous protocols to protect the safety of families and infants, we are proactively taking this action. 

About Perrigo

Perrigo Company plc is a leading provider of Consumer Self-Care Products and over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. Visit Perrigo online at www.perrigo.com

On November 1, 2022, Perrigo acquired Nestlé's Gateway Eau Claire, Wisconsin, plant, along with the U.S. and Canadian rights to the Good Start® infant formula brand. Perrigo operates the Good Start® infant formula brand in the United States and Canada.

SOURCE Perrigo


These press releases may also interest you

at 03:20
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...

at 03:00
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...

at 02:30
SOPHiA GENETICS , a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that Dhiti Omics Technologies, a precision molecular diagnostics service provider in India, is live on the SOPHiA...

at 01:15
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial...

at 01:05
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of Deutsche Numis as the Company's Financial and Capital Markets Adviser,...

3 jui 2024
YOUR LEGAL RIGHTS MAY BE AFFECTED There is a proposed settlement in a class-action lawsuit filed against Pfizer Inc., Pfizer Ireland Pharmaceuticals, Warner-Lambert Company, and Warner-Lambert Company LLC (collectively, "Pfizer") and Ranbaxy Inc.,...



News published on and distributed by: